Tempus AI won a $60 million contract from ARPA‑H to provide testing and contract research services for a project that uses biomarkers to develop adaptive treatment strategies in cancer. The award funds Tempus to deploy its molecular testing and analytics to support adaptive clinical research aimed at personalized oncology. The contract will pair Tempus’ data and laboratory capabilities with ARPA‑H’s mandate to accelerate high‑risk, high‑reward biomedical projects. Tempus said the work will focus on biomarker‑driven adaptive approaches that can rapidly iterate treatment strategies across patient subgroups. The win highlights government investment in AI‑enabled precision oncology and offers Tempus a platform to demonstrate scalable clinical utility for biomarker‑based adaptive designs.